OKLAHOMA CITY, Oct. 2, 2024 /PRNewswire/ -- Ambetter of Oklahoma, a product offered by a Centene Corporation (NYSE: CNC) company which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, announced today it will reduce plan premiums to residents in 36 counties in Oklahoma for 2025. Open enrollment for the Health Insurance Marketplace for Oklahoma runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Ambetter of Oklahoma is focused on improving our members' experiences by expanding our provider network and bringing down the cost of insurance," said Plan President and CEO of Oklahoma Complete Health Clay Franklin. "By reducing our plan premiums by 8%, we are excited to offer Oklahomans access to affordable and comprehensive coverage."
Ambetter of Oklahoma offers its members access to quality care, convenient services, and valuable rewards. 2025 benefits and offerings include:
Below is the full list of counties in which Ambetter of Oklahoma will be offered:
Oklahoma residents interested in learning more about Ambetter of Oklahoma or enrolling in a health plan during the open enrollment period may visit AmbetterofOklahoma.com.
About Ambetter of Oklahoma
Ambetter of Oklahoma serves under-insured and uninsured populations through the Federal Health Insurance Marketplace. Ambetter of Oklahoma is underwritten by Celtic Insurance Company, which is a Qualified Health Plan issuer in Oklahoma. For more information, visit ambetterhealth.com/en/ok/. This is a solicitation for insurance. For information on your right to receive an Ambetter of Oklahoma plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$63.75 |
Daily Change: | 1.97 3.19 |
Daily Volume: | 1,788,074 |
Market Cap: | US$33.530B |
October 30, 2024 October 25, 2024 September 11, 2024 August 29, 2024 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB